KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Current Deferred Revenue (2016 - 2023)

Biolife Solutions (BLFS) has disclosed Current Deferred Revenue for 14 consecutive years, with $422000.0 as the latest value for Q1 2023.

  • On a quarterly basis, Current Deferred Revenue fell 52.85% to $422000.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $422000.0, a 52.85% decrease, with the full-year FY2022 number at $548000.0, down 32.68% from a year prior.
  • Current Deferred Revenue was $422000.0 for Q1 2023 at Biolife Solutions, down from $548000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $944000.0 in Q2 2021 to a low of $324000.0 in Q4 2019.
  • A 5-year average of $640000.0 and a median of $605000.0 in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 187.35% in 2020, then crashed 54.34% in 2022.
  • Biolife Solutions' Current Deferred Revenue stood at $324000.0 in 2019, then skyrocketed by 187.35% to $931000.0 in 2020, then decreased by 12.57% to $814000.0 in 2021, then plummeted by 32.68% to $548000.0 in 2022, then decreased by 22.99% to $422000.0 in 2023.
  • Per Business Quant, the three most recent readings for BLFS's Current Deferred Revenue are $422000.0 (Q1 2023), $548000.0 (Q4 2022), and $429000.0 (Q3 2022).